Mid-Gestation Preeclampsia Screening Test Successfully Validated
By LabMedica International staff writers Posted on 18 Jul 2012 |
A mid-gestation preeclampsia-screening test correctly identifies 80% of women at risk for the development of preterm preeclampsia.
Pronota’s (Ghent, Belgium) assay, which tests for five protein biomarkers such that in conjunction with blood pressure measurement offers an improvement to existing tests. Proteomics platforms of Pronota were used to identify, verify, and validate a panel of novel blood biomarkers, which are predictive of preeclampsia at the mid-gestation time point. An unbiased large-scale proteomics biomarker-discovery experiment was followed by verification of the results in 300 women who either subsequently developed preeclampsia or did not.
The predictive merit of the biomarker panel was subsequently confirmed in another study of 300 women from a different population. In this validation study, the screening test identified 80% of the women who developed preeclampsia that resulted in birth of a premature baby (preterm preeclampsia). Pronota achieved these results through a longstanding scientific collaboration with Prof. Baker from the University of Alberta (Edmonton, AB, Canada), Prof. North from King’s College, London (United Kingdom), and Dr. Myers from Manchester Maternal & Fetal Health Research Center (United Kingdom).
The cohort used for the study was compiled by the the SCreening fOr Pregnancy Endpoints (SCOPE) Consortium who collected blood samples and gathered medical and lifestyle information from 5,600 women in six centers across Australia, New Zealand, the UK, and the Republic of Ireland over eight years. This controlled prospective study using high quality plasma samples and clinical data allowed for the rigorous and stepwise validation of Pronota’s test.
Dr. Jenny Myers, clinical senior lecturer, Manchester Maternal & Fetal Health Research Centre (United Kingdom) will present a discussion of the Pronota-SCOPE study at the International Society for the Study of Hypertension in Pregnancy meeting in Geneva (Switzerland) in July 2012.
Related Links:
Pronota
University of Alberta
King’s College, London
Pronota’s (Ghent, Belgium) assay, which tests for five protein biomarkers such that in conjunction with blood pressure measurement offers an improvement to existing tests. Proteomics platforms of Pronota were used to identify, verify, and validate a panel of novel blood biomarkers, which are predictive of preeclampsia at the mid-gestation time point. An unbiased large-scale proteomics biomarker-discovery experiment was followed by verification of the results in 300 women who either subsequently developed preeclampsia or did not.
The predictive merit of the biomarker panel was subsequently confirmed in another study of 300 women from a different population. In this validation study, the screening test identified 80% of the women who developed preeclampsia that resulted in birth of a premature baby (preterm preeclampsia). Pronota achieved these results through a longstanding scientific collaboration with Prof. Baker from the University of Alberta (Edmonton, AB, Canada), Prof. North from King’s College, London (United Kingdom), and Dr. Myers from Manchester Maternal & Fetal Health Research Center (United Kingdom).
The cohort used for the study was compiled by the the SCreening fOr Pregnancy Endpoints (SCOPE) Consortium who collected blood samples and gathered medical and lifestyle information from 5,600 women in six centers across Australia, New Zealand, the UK, and the Republic of Ireland over eight years. This controlled prospective study using high quality plasma samples and clinical data allowed for the rigorous and stepwise validation of Pronota’s test.
Dr. Jenny Myers, clinical senior lecturer, Manchester Maternal & Fetal Health Research Centre (United Kingdom) will present a discussion of the Pronota-SCOPE study at the International Society for the Study of Hypertension in Pregnancy meeting in Geneva (Switzerland) in July 2012.
Related Links:
Pronota
University of Alberta
King’s College, London
Latest Molecular Diagnostics News
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms